Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | SRD5A1 | P18405 | 5/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201637 | 1.00 | ALDH1A1 (0.46) | ALDH1A1GAAMEN1MAPTHPGD | |
| SCHEMBL7038721 | 0.87 | ALDH1A1 (0.61) | ALDH1A1GAAMEN1MAPTHPGD | |
| SCHEMBL25216589 | 0.79 | ALDH1A1 (0.73) | ALDH1A1GAAMEN1MAPTHPGD | |
| SCHEMBL31696344 | 0.79 | ALDH1A1 (0.73) | ALDH1A1GAAMEN1MAPTHPGD | |
| SCHEMBL2199560 | 0.78 | PDK2 (0.39) | ALDH1A1GAAMEN1MAPTHPGD | |
| SCHEMBL2199557 | 0.78 | PDK2 (0.39) | ALDH1A1GAAMEN1MAPTHPGD | |
| SCHEMBL12305892 | 0.78 | MAOB (0.44) | ALDH1A1MEN1MAPTKMT2ASRD5A1 | |
| SCHEMBL30423126 | 0.75 | ALDH1A1 (0.68) | ALDH1A1GAAMEN1MAPTHPGD | |
| SCHEMBL12305825 | 0.75 | EGFR (0.44) | ALDH1A1HPGDKDM4E | |
| SCHEMBL12428197 | 0.74 | KMT2A (0.48) | ALDH1A1GAAMEN1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977570-B2 | Dye-sensitized photoelectric conversion device | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977570-B2 | Dye-sensitized photoelectric conversion device | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977570-B2 | Dye-sensitized photoelectric conversion device | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20090084441-A1 | Dye-sensitized photoelectric conversion device | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-04-02 | — | — | US | disclosed |
| US-20090084441-A1 | Dye-sensitized photoelectric conversion device | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-04-02 | — | — | US | disclosed |
| US-20090084441-A1 | Dye-sensitized photoelectric conversion device | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-04-02 | — | — | US | disclosed |
| EP-1885015-A1 | DYE-SENSITIZED PHOTOELECTRIC CONVERSION DEVICE | Nippon Kayaku Kabushiki Kaisha (JP) | 2008-02-06 | — | — | EP | disclosed |
| EP-1885015-A1 | DYE-SENSITIZED PHOTOELECTRIC CONVERSION DEVICE | Nippon Kayaku Kabushiki Kaisha (JP) | 2008-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090084441-A1 | Dye-sensitized photoelectric conversion device | CRY1, H1-5, H1-0 | ALDH1A1 235/4885GAA 4576/4885MEN1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.